🌟 Big news in breast cancer treatment! The FDA has approved inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer. This innovative therapy offers new hope for patients who have faced recurrence after prior endocrine therapy.
Learn more about the significant trial outcomes and the role of the FoundationOne Liquid CDx companion diagnostic!
#SyenzaNews #BreastCancer #FDAApproval